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Purpose: To assess the efﬁcacy of ketogenic diet (KD) in adults with refractory epilepsy.
Methods: Eligible subjectswere 18–45 years oldwith at least twomonthly focal seizures (with orwithout
secondary generalization) documented by 8weeks’ follow-up. Classic form of KD treatment (90% fat) was
planned for 12 weeks: daily seizure diaries were kept and measurements of the urinary ketones were
recorded. Blood studies were done monthly and resting energy expenditure (REE), substrate utilization;
body composition and quality of life (QOL) were measured before and after intervention.
Results: Nine patients were enrolled (average age 28  6 years; seven women). Only two subjects
concluded the study per protocol due to an early drop-out. The average length of KD treatment was 8  4
weeks (two patients completed 12 weeks of KD; feelings of hunger and lack of efﬁcacy resulted in withdrawal
of the rest). The two patients who concluded the study had a more than 50% reduction in the frequency of the
seizures. The others experienced no improvement. Adherence to the KD protocol (100%) was documented by
constant ketonuria and increased fat utilization as indicated by the change in respiratory quotient (p < 0.031).
The KD increased the cholesterol levels (mainly LDL; p = 0.0001).
Conclusions: In our experience with relatively small adult population, adherence to KD is difﬁcult. In
patients who had compliance over 3 weeks (6/8), KD does not seem to have a signiﬁcant effect. Yet, the
signiﬁcant reduction in the two patients who concluded the study per protocol may indicate that some
patients may beneﬁt from this diet. Signiﬁcant increase in LDL levels and the unlikable dietary changes
are additional impediments to its implementation among adults with refractory epilepsy.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Considerable progress in understanding the pathophysiology of
epilepsy and its treatment has been made over recent years.
Despite the development of new drugs, invasive devices and the
ability to resect epileptic foci, epilepsy remains refractory to
treatment in about 30% of the patients.1 These patients face a
future with a severe and chronic disease manifested by uncon-
trolled seizures that can signiﬁcantly affect their quality of life
(QOL) and their mood as well as interfere with their ability to work
and to conduct a normal social life.1 Alternative effective treatment* Corresponding author at: The Department of Neurology, Tel Aviv Sourasky
Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel. Tel.: +972 3 6974874;
fax: +972 3 6092805.
E-mail address: mosek@tasmc.health.gov.il (A. Mosek).
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doi:10.1016/j.seizure.2008.06.001modalities are urgently needed. The development of a ketogenic
diet (KD) for the treatment of epilepsy followed the observation
that fasting could induce seizure control. Once a major therapeutic
modality in epilepsy, its implementation decreased with the
introduction of drug treatments, and it is currently reservedmainly
for children with uncontrolled seizures.2,3 There are several KD
protocols,2,4 and all are based on lipids, rather than carbohydrates,
as the main source of energy to the body. The calculation of the
daily caloric intake in the classical KD is based on the age and
gender of the subjects and the diet is constructed to supply very
high amount of fat and very low amount of carbohydrate (ratio 3:1)
and with close to normal protein content.2,4 It is assumed that the
ketone bodies that are formed during the diet play a major role in
seizure control.2,4
The efﬁcacy of KD treatment in epilepsy is mainly known from
observational studies. A Cochrane review found that there is no
reliable evidence from randomized controlled trials to support thevier Ltd. All rights reserved.
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the results of several large cohort studies the authors concluded
that ‘‘in those who have a difﬁcult to control epilepsy on multiple
modern antiepileptic drugs, we consider a ketogenic diet a valid
option’’.5 These studies report that a signiﬁcant seizure control can
be achieved in children treated with KD, reaching a greater than
50% reduction in the frequency of the seizures in more than half of
them.2 In the largest reported prospective study, out of 150
children treated with KD, 3% were seizure free after 3 months, 31%
gainedmore than 90% reduction in their seizure frequency and 26%
had 50–90% reduction in the frequency of the seizures.3
In adults, on the other hand, the practice of KD in the
treatment of epilepsy is uncommon and its efﬁcacy in this age
group is practically unknown. Almost eight decades ago,
Barborka6 reported that among 100 adults treated with KD
for epilepsy, 12% were seizure free after 1 year and 44% had
signiﬁcant improvement. Contemporary information is very
sparse. In their small case series, Sirven et al.7 reported that 3
out of 11 patients with refractory epilepsy gained 90% frequency
reduction and another 3 patients had a 50–89% frequency
reduction after 8 months of KD treatment. In one 20-year-old
patient with refractory epilepsy, Schiff et al. reported that KD
treatment reduced the seizure frequency from daily seizures to
5–7 in 1 month.8
The current prospective pilot study aimed to evaluate the
efﬁcacy and tolerability of KD treatment in adults with refractory
epilepsy. We also assessed the inﬂuence of the KD on their lipid
proﬁle, energy expenditure and body composition as well as on
their QOL.
Methods
This was an open prospective study. The research received prior
approval by the ethical committee of our institution.
The study population
Subjects were recruited from our outpatient epilepsy clinic.
After they signed informed consent, we included males and
females 18–45 years old who were diagnosed as having epilepsy
with focal seizures with or without secondary generalization for at
least 2 years. Each had 2 seizures monthly in spite of treatment
with at least three major antiepileptic drugs at therapeutic levels.
We included patients in whom the KD requirements could be
ascertained being independent or helped by a caregiver. Exclusion
criteria were current treatment with topiramate or acetazolamide,
concurrent diabetes mellitus, arterial hypertension, cerebrovas-
cular and peripheral vascular diseases, abnormal electrocardio-
gram, history of hyperlipidemia or chronic kidney or liver disease
or known inherited metabolic disorder.
Study procedure
Patients who met the inclusion criteria completed a baseline
daily seizures diary for 8 weeks (with the help of family members
when needed). Assessment of caloric intake, including the
contribution of the different macronutrients, over the last 2
months was done by a certiﬁed clinical nutritionist experienced
with KD treatment in children and using retrospective recall data
as well as prospective 3-day food records. Classic form of KD
treatment (90% fat) was planned for 12 weeks. The KD treatment
was begun with 1 week of gradual induction until reaching
medium-high levels [50–150 mg/dl (5–15 mmol/L)] of ketonuria
(early morning self assessment; Choiceline 10, Roche). Daily
seizure diarieswere kept andmeasurements of the urinary ketoneswere recorded. Efﬁcacywas established as equal to or>50% seizure
reduction compared to baseline seizure frequency.
Ancillary studies
Lipid levels, electrolytes, liver and kidney functions were
assessed at baseline and every 4 weeks during the treatment
period and 4 weeks post-treatment (or when the patients
withdrew from the study). Resting energy expenditure (REE)
was measured by an open-circuit indirect calorimeter (Delta-
trac, Helsinki, Finland) in order to assess the effect of the diet on
energy needs. Patients fasted (water drinking was allowed) from
20.00 h the night preceding the test which was carried out the
next morning. They lay supine for 30 min prior to evaluation at
08.00. After calibration with standardized oxygen and carbon
dioxide gas concentrations (95% O2 5% CO2), a plastic canopy
was placed over the patient’s head and REE was measured for
1 h. There was a 10-min washout period before starting data
collection. The inter-individual coefﬁcient of variation in our
laboratory is <3%. The respiratory quotient (RQ) was determined
based on the above measurements (RQ value of 1 indicated
exclusive carbohydrate utilization while RQ of 0.7 indicated
exclusive lipid utilization).9 The average RQ of healthy controls
in our laboratory is 0.83  0.04.10
Fat and lean body mass (fat-free mass) were determined by a
dual energy X-ray absorptiometry (DEXA) prior to implementation
of the diet and at 3 months in order to assess the inﬂuence of the
KD on body composition.11
The QOL of the patients was evaluated with QOL31, a
questionnaire for patients with epilepsy that assesses seven areas:
seizure worry, emotional well-being, energy/fatigue, cognition,
social function, medical effects and overall QOL.12 The patients
ﬁlled in the questionnaire at baseline and at 3 months.
Data were analyzed by paired or unpaired t-tests, as appro-
priate.
Results
Forty-seven patients diagnosed with intractable epilepsy were
screened. Twenty (43%) patients did not meet the study criteria
(such as fewer than two attacks/month, use of carbonic anhydrase
inhibitors) and 18 (38%) patients declined to participate (unwilling
to change their diet). Nine (19%) patients were eligible and agreed
to enroll in the study but one withdrew from the study during the
KD induction week due to diarrhea. The characteristics of the
remaining eight patients are given in Table 1. The average age of
the participants was 28  6 years, and therewere seven females. The
average duration of epilepsy was 20  8 years (range 5–27 years) and
the patients had a mean of 14  15 (range 2–49) focal seizures in 1
week during the 8-week baseline follow-up. They were being treated
by one to three antiepileptic drugs at the time of study entry.
KD treatment
The contribution of the different macronutrients to the diet
before and during the study and the average caloric intake are
given in Table 2. Total caloric intake tended to increase during the
study (1658  613 kcal/day vs. 1916  241 kcal/day) due to feeling
of hunger and or documented weight loss, maintaining the basic 3:1
ratio. Ketonuria was achieved in all of the participants during the
week of gradual KD build-up and it was kept at medium–high levels
during the whole study, except for one patient, probably due to low
compliance (Table 1).
The average duration of the KD treatment was 8  4 weeks
(average  S.D.; range 1–12 weeks; Table 1). An early dropout from
Table 2
Diet composition before and during the study
Macronutrients Before study During study p<
Total caloric intake (kcal/day) 1658  613 1916  241 0.44
Carbohydrates (%)a 44.99  12.10 2.61  0.07 0.031
Fat (%) 36.40  14.48 87.10  0.02 0.031
Protein (%) 19.07  5.15 10.76  1.05 0.031
a Percentage of total caloric intake.
Table 1
Average weekly seizure frequency during baseline follow-up, during KD treatment and average urine ketones level during KD treatment
Patient Gender Age (year) Epilepsy
duration (year)
Average weekly seizure
frequency at baseline
 S.D. (range)
KD duration
(weeks)
Average weekly seizure
frequency during
KD  S.D. (range)
Average weekly
urine ketones levels
during KD (mg/dl)
1 M 36 25 49  31 (12–108) 12 15  5 (7–26) 87
2 F 26 25 2  1 (0–4) 12 1  1 (0–3) 45
3 F 28 27 19  5 (8–28) 11 20  7 (9–32) 9
4 F 36 15 4  2 (0–7) 10 6  6 (0–15) 103
5 F 23 11 4  2 (1–7) 8 3  3 (0–9) 80
6 F 36 24 18  3 (14–24) 6 27  4 (24–33) 126
7 F 26 24 20  18 (10–64) 3 17  1 (16–17) 96
8 F 25 24 3  1 (1–5) 1 7 –
S.D.: standard deviation.
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were lack of efﬁcacy (patients #4 and #6), feeling of hunger (patient
#7), jaw fracture consequent to seizure (patient #8) and hyper-
triglyceridemia (patient #5).
Seizure frequency
High KD treatment efﬁcacy (>50% seizure reduction) was found
in the only two subjects who completed the study according to the
protocol. No signiﬁcant decrease in the seizure frequency was
foundwhenwe analyzed those subjects who concluded 3weeks or
more of the KD (6/8) (Table 1). These changes were noted after 1–2
weeks of the KD treatment and lasted throughout the entire
treatment period. The change in the seizure frequency during the
KD treatment or the degree of ketonuria was unrelated to the age
or the gender of the patients, nor to the duration of the epilepsy or
the baseline seizure frequency (Table 1).
Metabolic tests
Elevated lactic dehydrogenase levels were detected in one
patient prior and during the study (425 U/L) and in two other
patients during the study (470 U/L, returning to normal value at
the post-study test). The electrolytes, kidney and liver functions
studies were in the normal range prior and during the study. TheTable 3
Lipid proﬁle
n Total chol. av.  S.D.
(range) (mg/dl)
LDL
(mg
Normal range (mg/dl) 150–200 60
Baseline 9 199  24(172–236) 115
4–7 weeks of KD 6 251  52a (196–300) 152
11–12 weeks of KD 3 266  25b (238–287) 177
5 weeks (av.) post-study 6 207  22 (177–231) 110
Baseline, in-study and post-study values. chol.: cholesterol; av.: average; S.D.: stand
ketogenic diet.
a p < 0.02 compared to baseline.
b p < 0.002 compared to baseline.
c p < 0.03 compared to baseline.
d p < 0.0001 compared to baseline.average baseline total cholesterol levels were in the upper normal
range, with values of low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) within normal ranges, permitting study
inclusion (Table 3). The KD resulted in a 26% increase of the total
cholesterol values after 4–7 weeks (n = 6) of treatment and by 33%
after 11–12 weeks (n = 3). Similarly, LDL values increased by 32%
and 54%, respectively, with no change in the HDL levels.
Triglyceride levels remained within the normal range except in
one patient, in whom a high level (834 mg/dl; normal range 50–
175 mg/dl) after 6 weeks on the diet necessitated termination of
the diet: his triglyceride levels subsequently returned to normal.
Six patients who completed at least 6 weeks of KD treatment
had a mean weight loss of 2.8 kg  1 after 4–6 weeks of treatment.
These changes occurred despite the increase in the caloric intake and
a decrease of 4%  2.6 in the REE during the diet compared to the
baseline values (Table 4). DEXA studies revealed no change in the lean
body mass while on the diet, while the total body fat content
decreased by 4%  2 compared to the baseline values (Table 4). The
respiratory quotient decreased during the diet (0.83  0.04 vs.
0.73  0.02), indicating a higher fat substrate utilization on the KD.
QOL
The patients’ baseline QOL scorewas low, averaging 42 17, and
it remained in the lower range (51  22) in the six patients who had
8  2weeks of treatment. Three subjects (patients #2, #3, and #5) had
an increase in their QOL, mainly due to increased cognition (alertness
andconcentration),while eithernochangeoradecrease in theQOLwas
noted in the other ﬁve. The changes in the QOL were unrelated to the
accompanying changes in the frequency of the seizures.
Discussion
KD in adult patients with epilepsy seems to be hard to perform
as indicated by the high rate of dropout in our study. High KDav.  S.D. (range)
/dl)
HDL av.  S.D.
(range) (mg/dl)
Triglycerides av.  S.D.
(range) (mg/dl)
–160 35–70 50–175
 20 (79–140) 69  24 (44–120) 78  36 (46–158)
 38c (113–167) 69  22 (45–109) 218  302 (78–834)
 20d (154–193) 70  6 (62–74) 98  44 (53–140)
 28 (77–161) 84  23 (50–115) 67  30 (33–104)
ard deviation; LDL: low-density lipoprotein; HDL: high-density lipoprotein; KD:
Table 4
Changes in anthropometric and nutritional parameters during the study
Baseline At 4–6 weeks of KD p<
Weight (kg) 57.9  7.3 55.6  5.5 0.063
BMI (kg/m2) 20.65  3.03 19.82  2.41 0.063
LBM (kg) 40.42  5.95 40.88  5.25 0.84
Body fat (%) 28.17  9.83 23.77  7.29 0.031
Caloric intake (kcal/day) 1658  613 1916  241 0.44
REE (kcal/day) 1327  88 1272  83 0.031
RQ 0.83  0.04 0.73  0.02 0.031
KD: ketogenic diet; BMI: body mass index; LBM: lean body mass; REE: respiratory
energy expenditure; RQ: respiratory quotient.
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two subjects who completed the study according to the protocol.
Since the effect of KD is seen already after 3 weeks of treatment we
also analyzed those subjectswho concluded 3weeks ormore of the
KD (6/8), however, no signiﬁcant decrease in the seizure frequency
was found. Noteworthy, the three patients who maintained the
11–12weeks protocol were dependent on their familymembers in
terms of food supply. One can assume, therefore, that the dietary
limitations imposed by the KD could be an obstacle for
independent adults to continue a long-term treatment, while it
might be achievable in young children.
The change in the respiratory quotient13,14 and the high levels
of ketonuria (except patient #3) indicate the compliance of our
patients to the KD and exclude non-adherence. Moreover, the level
of ketonuria and the change in respiratory quotient did not
correlate with the seizure frequency, and nor did the patients’ age,
gender and the duration of the epilepsy or the baseline frequency
of the seizures.
Three of our patients noted a higher sense of alertness and
concentration, a recognized effect of the KD,2 but overall group
QOL did not change to any great extent and remained low. They
remainedwith frequent seizures and disabling disease. In addition,
the dietary limitations reduced food enjoyment and added a
sensation of hunger. Over one-third (38%) of the patients who met
the inclusion criteria refused to participate due to the dietary
limitations, despite knowing that no other optional treatment is
currently available. The resignation of oneself to a life with
epilepsy might interfere with complying with a treatment that
demands changes in lifestyle (special food preparation and
restricted diet) and therefore not suitable for most independent
adults with refractory epilepsy.
These results are vastly different from those reported in the
pediatric age rangewhere 3months of treatmentwith KD achieved
more than a 50% reduction in the frequency of the seizures in 60%
of the children.3 Previous reports on adults also indicated higher
efﬁcacy in refractory epilepsy.7,8 Although in some patients there
was a change in the seizure frequency we cannot exclude that
these changes are not due to the random ﬂuctuation seen in the
disease or to a placebo effect due to the fact that the patients were
aware of the type of diet being used. It is also possible that the
duration of the epilepsy in our patients contributed to the low
effectiveness of the KD treatment.
The metabolic changes which were observed during this study
are interesting since in spite of a tendency for higher caloric intake,
all of the six patientswho completed 6weeks of the KD lost weight.
This weight loss was due to a decrease in body fat mass and not totheir lean bodymass, as was previously reported in subjects on the
Atkins diet.15 Loss of weight during the diet was also previously
described in children under KD treatment.16Weight loss in the face
of decreased resting energy expenditure and a tendency to higher
caloric intake is not easy to explain and may be due to fat
malabsorption caused by the high fat content of the diet or to a
change in metabolic pathways, similarly to the Atkins diet.15
The KD treatment resulted in a considerable and progressive
increase, although reversible, of the cholesterol levels (mainly
LDL). This previously reported adverse event17 leads us to
reconsider long-term usage of KD in adults. The high levels of
cholesterol recorded prior to the study (199  24 mg/dl) may be
associated with the usage of carbamazepine by six of our eight
patients.16 No other major changes were noted during the KD
treatment, except for a single and reversible increase in the
triglyceride value measured in one patient.
The results of this pilot study, in a relatively small population of
adults with refractory epilepsy, showed that most of our patients
could not adhere with the diet. While the two who completed the
study beneﬁted signiﬁcantly, no signiﬁcant change was found in
the others. A signiﬁcant increase in LDL levels and unpleasant
dietary changes are additional impediments to the implementa-
tion of this treatment among adult patients.
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